Paula Poikonen-Saksela Selected Research

Epirubicin (Ellence)

1/2022	Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial.
7/2020	Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000-1.
6/2017	Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paula Poikonen-Saksela Research Topics

Disease

8	Breast Neoplasms (Breast Cancer) 10/2023 - 06/2017
4	Neoplasms (Cancer) 05/2023 - 06/2017
2	Triple Negative Breast Neoplasms 10/2023 - 06/2017
1	Medically Unexplained Symptoms 01/2022
1	Leukopenia 07/2020

Drug/Important Bio-Agent (IBA)

3	Epirubicin (Ellence)FDA LinkGeneric 01/2022 - 06/2017
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 06/2017
2	Estrogen ReceptorsIBA 01/2022 - 06/2017
2	Capecitabine (Xeloda)FDA Link 01/2022 - 06/2017
2	Docetaxel (Taxotere)FDA Link 01/2022 - 06/2017
1	SolutionsIBA 05/2023
1	BuffersIBA 01/2022
1	AnthracyclinesIBA 01/2022
1	taxaneIBA 01/2022
1	TabletsIBA 05/2021
1	human ERBB2 proteinIBA 06/2017
1	Hormones (Hormone)IBA 06/2017
1	Progesterone Receptors (Progesterone Receptor)IBA 06/2017
1	SteroidsIBA 06/2017

Therapy/Procedure

5	Therapeutics 10/2023 - 01/2021
3	Drug Therapy (Chemotherapy) 10/2023 - 07/2020
3	Adjuvant Chemotherapy 01/2022 - 07/2020